Loading data for MDGL — first visit, this takes a few seconds.

提醒

Madrigal Pharmaceuticals ... (MDGL)

NasdaqGS: MDGL · 实时价格 · USD

524.87

+17.31 (3.41%)

收盘价： Aug 17, 2026, 8:00 PM

524.52

-0.07%

盘后: 7:30 PM

3.41% (1D)

暂无数据

买价	n/a
市值	12.13B
营收（TTM）	1.28B
净利润（TTM）	-325.1M
贝塔值	-1.00
每股收益（TTM）	-14.49
市盈率（TTM）	n/a
预期市盈率	54.53
市净率（TTM）	23.14
市销率（TTM）	9.44
Earnings Date	Nov 4, 2026

卖价	n/a
成交量	307,423
20日均量	362,919
开盘价	509.16
前收盘价	507.56
日内区间	506.85 - 527.22
52周区间	351.32 - 615.00
分析师	n/a
目标价	n/a
分红	n/a
除息日	n/a

关于 MDGL

Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania....

[阅读更多]

行业 Biotechnology

板块 Healthcare

上市日期 Feb 6, 2007

员工人数 915

交易所 NasdaqGS

股票代码 MDGL

官网 https://www.madrigalpharma.com

公司完整简介

财务表现

2025年，Madrigal Pharmaceuticals的营收为958.4M，较上一年的180.13M增长432.05%。净利润为-288.28M，下降-38.12%。

财务报表

财报意外

Madrigal Pharmaceuticals 已于 Jul 30, 2026 发布季度财报：

营收为 $364.25M 低于预期 $0, ， 71.17% 同比增长.

每股收益为 -1.99 超出预期 0.24, ， -4.74% 同比下滑.

下次财报发布时间

Madrigal Pharmaceuticals Inc. 计划于以下时间发布财报 Nov 4, 2026, 开盘前。
分析师预计营收为 ... 升级

新闻

3天前 · MarketBeat

Madrigal’s Rezdiffra Hits $1.3B Run Rate as MASH Pipeline Expands

Madrigal Pharmaceuticals (NASDAQ:MDGL) said Rezdiffra continued to post strong commercial growth in the second quarter of 2026, while the company expanded its development pipeline around the MASH ther...

2周前 · The Fly

Walmart downgraded, Palantir upgraded: Wall Street's top analyst calls

2周前 · 24/7 Wall St.

Here Are Tuesday’s Top Wall Street Analyst Research Calls: Apple, CoreWeave, eBay, Exxon Mobil, Intuit, Nebius Group, Palantir Technologies, SK hynix, and More

Wall Street wasted no time Monday, sending the Nasdaq surging past 25,900 while analysts took aim at some of the market's biggest names with fresh upgrades, downgrades, and new coverage that could res...

2周前 · Simply Wall St.

Madrigal Pharmaceuticals (MDGL) Beat Earnings Estimates, Is It Still Below Fair Value?

Madrigal Pharmaceuticals (MDGL) drew attention after its second quarter 2026 earnings release, which highlighted Rezdiffra sales growth, stronger patient uptake, a smaller than expected quarterly loss...

2周前 · Zacks

MDGL Stock Down Despite Q2 Beat, MASH Drug Drives Top-Line Y/Y Growth

Madrigal beats Q2 estimates as Rezdiffra sales lift revenues 71% year over year, but shares fall as investors weigh slower commercial growth.

第 1 页，共 2 页